ReviewRNA biology2025
Diverse RNAs in human umbilical cord-derived exosomes and their therapeutic potential.
Review in RNA biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes, nanosized extracellular vesicles (30-150 nm) secreted by various cell types, have emerged as crucial mediators of intercellular communication and promising therapeutic agents. This review highlights the diverse RNA cargo of exosomes derived from human umbilical cord mesenchymal stem cells (HucMSC-Exos), including mRNAs, miRNAs, long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), which regulate gene expression and cellular functions in target cells. The mechanisms of exosome biogenesis, release, and uptake are discussed, with emphasis on their ability to cross biological barriers such as the blood - brain barrier. HucMSC-derived exosomes exhibit therapeutic potential in wound healing, angiogenesis, neuroprotection, immunomodulation, and treatment of diseases like Parkinson's, preeclampsia, and renal or hepatic injury. Specific exosomal miRNAs, such as miR-136, miR-335-5p, and miR-1246, demonstrate targeted effects. Additionally, exosomal RNAs show promise as disease biomarkers. Future directions involve standardization, targeted engineering, RNA profiling, clinical trials, and integration into personalized medicine strategies for regenerative therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.